pharmask limited
pharmask limited Company Information
Company Number
08869947
Website
-Registered Address
2nd floor nucleus house, 2 lower mortlake road, richmond, TW9 2JA
Industry
Non-trading company
Telephone
-
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
kenneth moore 100%
pharmask limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMASK LIMITED at £97k based on a Turnover of £256.7k and 0.38x industry multiple (adjusted for size and gross margin).
pharmask limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMASK LIMITED at £0 based on an EBITDA of £-23.5k and a 3.08x industry multiple (adjusted for size and gross margin).
pharmask limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMASK LIMITED at £174.3k based on Net Assets of £80.7k and 2.16x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharmask Limited Overview
Pharmask Limited is a live company located in richmond, TW9 2JA with a Companies House number of 08869947. It operates in the non-trading company sector, SIC Code 74990. Founded in January 2014, it's largest shareholder is kenneth moore with a 100% stake. Pharmask Limited is a established, micro sized company, Pomanda has estimated its turnover at £256.7k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pharmask Limited Health Check
Pomanda's financial health check has awarded Pharmask Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 7 areas for improvement. Company Health Check FAQs
2 Strong
1 Regular
7 Weak
Size
annual sales of £256.7k, make it smaller than the average company (£2.9m)
- Pharmask Limited
£2.9m - Industry AVG
Growth
3 year (CAGR) sales growth of -23%, show it is growing at a slower rate (4.4%)
- Pharmask Limited
4.4% - Industry AVG
Production
with a gross margin of 19.3%, this company has a higher cost of product (36.5%)
- Pharmask Limited
36.5% - Industry AVG
Profitability
an operating margin of -9.1% make it less profitable than the average company (5.6%)
- Pharmask Limited
5.6% - Industry AVG
Employees
with 1 employees, this is below the industry average (34)
- Pharmask Limited
34 - Industry AVG
Pay Structure
on an average salary of £37.8k, the company has an equivalent pay structure (£37.8k)
- Pharmask Limited
£37.8k - Industry AVG
Efficiency
resulting in sales per employee of £256.7k, this is more efficient (£134.5k)
- Pharmask Limited
£134.5k - Industry AVG
Debtor Days
it gets paid by customers after 116 days, this is later than average (40 days)
- Pharmask Limited
40 days - Industry AVG
Creditor Days
its suppliers are paid after 0 days, this is quicker than average (42 days)
- Pharmask Limited
42 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pharmask Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Pharmask Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1.5%, this is a lower level of debt than the average (41.4%)
1.5% - Pharmask Limited
41.4% - Industry AVG
PHARMASK LIMITED financials
Pharmask Limited's latest turnover from March 2023 is estimated at £256.7 thousand and the company has net assets of £80.7 thousand. According to their latest financial statements, we estimate that Pharmask Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | 1 | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 81,912 | 106,332 | 132,786 | 172,196 | 198,114 | 53,261 | 66,627 | 1,755 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30,714 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 81,912 | 106,332 | 132,786 | 172,196 | 198,114 | 53,261 | 66,627 | 32,469 | 0 |
| total assets | 81,912 | 106,332 | 132,786 | 172,196 | 198,114 | 53,261 | 66,627 | 32,469 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 413 | 1,359 | 11,940 | 32,733 | 50,707 | 5,209 | 17,991 | 10,742 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 413 | 1,359 | 11,940 | 32,733 | 50,707 | 5,209 | 17,991 | 10,742 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 825 | 825 | 825 | 825 | 1,100 | 1,000 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 960 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 825 | 825 | 825 | 825 | 1,100 | 1,000 | 960 | 0 | 0 |
| total liabilities | 1,238 | 2,184 | 12,765 | 33,558 | 51,807 | 6,209 | 18,951 | 10,742 | 0 |
| net assets | 80,674 | 104,148 | 120,021 | 138,638 | 146,307 | 47,052 | 47,676 | 21,727 | 0 |
| total shareholders funds | 80,674 | 104,148 | 120,021 | 138,638 | 146,307 | 47,052 | 47,676 | 21,727 | 0 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | |||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -24,420 | -26,454 | -39,410 | -25,918 | 144,853 | -13,366 | 64,872 | 1,755 | 0 |
| Creditors | -946 | -10,581 | -20,793 | -17,974 | 45,498 | -12,782 | 7,249 | 10,742 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | -275 | 100 | 1,000 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | -960 | 960 | 0 | 0 |
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | -30,714 | 30,714 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | -30,714 | 30,714 | 0 |
pharmask limited Credit Report and Business Information
Pharmask Limited Competitor Analysis
Perform a competitor analysis for pharmask limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in TW9 area or any other competitors across 12 key performance metrics.
pharmask limited Ownership
PHARMASK LIMITED group structure
Pharmask Limited has no subsidiary companies.
Ultimate parent company
PHARMASK LIMITED
08869947
pharmask limited directors
Pharmask Limited currently has 2 directors. The longest serving directors include Mr Kenneth Moore (Jan 2014) and Mr Alexander Moore (Mar 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Kenneth Moore | United Kingdom | 68 years | Jan 2014 | - | Director |
| Mr Alexander Moore | United Kingdom | 23 years | Mar 2021 | - | Director |
P&L
March 2023turnover
256.7k
-20%
operating profit
-23.5k
0%
gross margin
19.3%
+15.06%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
80.7k
-0.23%
total assets
81.9k
-0.23%
cash
0
0%
net assets
Total assets minus all liabilities
pharmask limited company details
company number
08869947
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
January 2014
age
10
incorporated
UK
accounts
Micro-Entity Accounts
ultimate parent company
previous names
N/A
last accounts submitted
March 2023
address
2nd floor nucleus house, 2 lower mortlake road, richmond, TW9 2JA
accountant
-
auditor
-
pharmask limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pharmask limited.
pharmask limited Companies House Filings - See Documents
| date | description | view/download |
|---|
